Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies
Glioblastoma is the most frequent primary neoplasm of the central nervous system and still suffers from very poor therapeutic impact. No clear improvements over current standard of care have been made in the last decade. For other cancers, but also for brain metastasis, which harbors a very distinct...
Main Authors: | Vassilis Genoud, Denis Migliorini |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/7/3493 |
Similar Items
-
Current Immunotherapeutic Strategies for the Treatment of Glioblastoma
by: Mark Dapash, et al.
Published: (2021-09-01) -
The role of CMV in glioblastoma and implications for immunotherapeutic strategies
by: Maryam Rahman, et al.
Published: (2019-01-01) -
Immunotherapeutic advancements for glioblastoma
by: Leonel eAmpie, et al.
Published: (2015-01-01) -
CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma
by: Luke Maggs, et al.
Published: (2021-05-01) -
Targeting CDK9 for the Treatment of Glioblastoma
by: Alice Ranjan, et al.
Published: (2021-06-01)